ClinicaliQ Trial Snapshot
- IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients — Active Not Recruiting • Phase II / Phase III • Oncology • NCT01398085.
- Study testing whether radioactive iodine treatment is needed after surgery for low-risk thyroid cancer patients.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients. Conditions: Thyroid Cancer, Thyroid Neoplasms Interventions: I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation Lead Sponsor: University College, London Planned Enrollment: 504 participants